Novo Nordisk A/S (NYSE:NVO) Stock Price Down 2.3% – Time to Sell?

11 Apr 2025, 18:54 by Doug Wharley · The Cerbat Gem

Novo Nordisk A/S (NYSE:NVO – Get Free Report) dropped 2.3% during mid-day trading on Wednesday . The stock traded as low as $59.52 and last traded at $60.21. Approximately 3,089,586 shares traded hands during trading, a decline of 46% from the average daily volume of 5,691,533 shares. The stock had previously closed at $61.60.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NVO. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Monday. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Read Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market capitalization of $290.59 billion, a PE ratio of 19.68, a P/E/G ratio of 0.90 and a beta of 0.61. The stock has a 50-day simple moving average of $78.23 and a 200 day simple moving average of $93.98.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of large investors have recently bought and sold shares of the stock. GQG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $404,910,000. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock valued at $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $158,657,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

(Get Free Report)